EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte Studie

Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study

Lin Zhao, Hong Chen, Zhifeng Cheng, Hongwei Jiang, Yibing Lu, Jianzhong Xiao, Xinhua Xiao, Yuanyuan Li iD, Yuan Yuan, Xiaoying Li iD

Obesity · 2025

DOI: 10.1002/oby.24306 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, 2025. Written by Lin Zhao and 9 co-authors. Institution: Zhongshan Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Cardiovascular Diseases, Metabolic Syndrome, Obesity, Triglycerides. 20 references. Funded by: Eli Lilly and Company.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

The objective of this study was to evaluate the association of tirzepatide with body weight, cardiometabolic markers, and metabolic syndrome in Chinese participants achieving normal body mass index (BMI) values by week 52 across baseline BMI subgroups.

Methods

This post hoc analysis of SURMOUNT‐CN assessed the association of tirzepatide with cardiometabolic risk factors in Chinese participants, categorized by Chinese‐specific anthropometric cutoffs for BMI and waist circumference. The association of early weight loss (greater or less than median at 12 and 24 weeks) with cardiometabolic markers and metabolic syndrome was evaluated.

Results

In this post hoc analysis ( N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers. Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo ( p < 0.05). At week 52, 37 participants achieved a normal BMI (18.5–24 kg/m 2 , Chinese criteria), and metabolic syndrome dropped from 21.6% at baseline to 0%.

Conclusions

Early weight loss with tirzepatide was associated with significant improvements in cardiometabolic risk factors, particularly in Chinese adults achieving a normal BMI by week 52, suggesting that early response may be associated with enhanced long‐term metabolic health outcomes.

Subjects

MeSH terms (MEDLINE)

Cardiovascular DiseasesMetabolic SyndromeObesityTriglyceridesAdultFemaleHumansMaleMiddle AgedBiomarkersBody Mass IndexBody WeightCardiometabolic Risk FactorsChinaDouble-Blind MethodTirzepatideWaist CircumferenceWeight LossEast Asian People

Substances

BiomarkersTirzepatideTriglycerides

Authors and institutions

  • Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
  • The First Affiliated Hospital of Henan University of Science and Technology, Henan, China.
  • The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Beijing Tsinghua Changgung Hospital, Beijing, China.

ORCID profiles: Yuanyuan Li, Xiaoying Li

Funding

  • Eli Lilly and Company

Cite

APA

Zhao, L., Chen, H., Cheng, Z., Jiang, H., Lu, Y., Xiao, J., Xiao, X., Li, Y., Yuan, Y., & Li, X. (2025). Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study. Obesity. https://doi.org/10.1002/oby.24306

Vancouver

Zhao L, Chen H, Cheng Z, Jiang H, Lu Y, Xiao J, et al. Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study. Obesity. 2025. doi:10.1002/oby.24306

BibTeX
@article{Zhao2025,
  author = {Zhao, Lin and Chen, Hong and Cheng, Zhifeng and Jiang, Hongwei and Lu, Yibing and Xiao, Jianzhong and Xiao, Xinhua and Li, Yuanyuan and Yuan, Yuan and Li, Xiaoying},
  title = {Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study},
  journal = {Obesity},
  year = {2025},
  doi = {10.1002/oby.24306}
}
Start for free →